BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 24643403)

  • 1. Impacts of patient characteristics on the effectiveness of landiolol in AF/AFL patients complicated with LV dysfunction: Subgroup analysis of the J-Land study.
    Kinugawa K; Nagai R; Inoue H; Atarashi H; Seino Y; Yamashita T; Shimizu W; Aiba T; Kitakaze M; Sakamoto A; Ikeda T; Imai Y; Daimon T; Fujino K; Nagano T; Okamura T; Hori M;
    Adv Ther; 2014 Apr; 31(4):426-39. PubMed ID: 24643403
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Urgent management of rapid heart rate in patients with atrial fibrillation/flutter and left ventricular dysfunction: comparison of the ultra-short-acting β1-selective blocker landiolol with digoxin (J-Land Study).
    Nagai R; Kinugawa K; Inoue H; Atarashi H; Seino Y; Yamashita T; Shimizu W; Aiba T; Kitakaze M; Sakamoto A; Ikeda T; Imai Y; Daimon T; Fujino K; Nagano T; Okamura T; Hori M;
    Circ J; 2013; 77(4):908-16. PubMed ID: 23502991
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of Landiolol and Digoxin as an Intravenous Drug for Controlling the Heart Rate in Patients with Atrial Fibrillation and Severely Depressed Left Ventricular Function.
    Shinohara M; Wada R; Yano K; Akitsu K; Koike H; Kinoshita T; Suzuki T; Fujino T; Ikeda T
    Int Heart J; 2020 Sep; 61(5):944-950. PubMed ID: 32921677
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential Effectiveness of Landiolol Between Atrial Fibrillation and Atrial Flutter/Atrial Tachycardia Patients With Left Ventricular Dysfunction.
    Oka E; Iwasaki YK; Maru E; Fujimoto Y; Ito-Hagiwara K; Hayashi H; Yamamoto T; Yodogawa K; Hayashi M; Shimizu W
    Circ J; 2019 Mar; 83(4):793-800. PubMed ID: 30814430
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design of a prospective observational survey on landiolol in atrial fibrillation/atrial flutter patients with chronic heart failure - AF-CHF landiolol survey.
    Yamashita T; Saitoh T; Matsushita M
    J Cardiol; 2015 Jul; 66(1):69-72. PubMed ID: 25454208
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Open-Label Two-Dose Pilot Study of Landiolol for the Treatment of Atrial Fibrillation/Atrial Flutter in Caucasian Patients.
    Stix G; Wolzt M; Domanovits H; Kadlecová P; Husch B; Trebs M; Hodisch J; Unger M; Krumpl G
    Circ J; 2019 Dec; 84(1):33-42. PubMed ID: 31813897
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alteration of fatal 1:1 conducted atrial flutter to less conducted ratio by landiolol infusion.
    Takata J; Haruyama N; Arashi T; Mae T
    J Anesth; 2016 Aug; 30(4):716-9. PubMed ID: 27085543
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A prospective observational survey on landiolol in atrial fibrillation/atrial flutter patients with chronic heart failure - AF-CHF landiolol survey.
    Yamashita T; Nakasu Y; Mizutani H; Sumitani K
    J Cardiol; 2019 Nov; 74(5):418-425. PubMed ID: 31255463
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of landiolol hydrochloride, an ultra-short-acting beta 1-selective blocker, on supraventricular tachycardia, atrial fibrillation and flutter after pulmonary resection.
    Nakano T; Shimizu K; Kawashima O; Kamiyoshihara M; Nagashima T; Ibe T; Takeyoshi I
    J Clin Pharm Ther; 2012 Aug; 37(4):431-5. PubMed ID: 22059486
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Canadian Cardiovascular Society atrial fibrillation guidelines 2010: rate and rhythm management.
    Gillis AM; Verma A; Talajic M; Nattel S; Dorian P;
    Can J Cardiol; 2011; 27(1):47-59. PubMed ID: 21329862
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of landiolol hydrochloride for atrial fibrillation after open heart surgery.
    Nishi H; Sakaguchi T; Miyagawa S; Yoshikawa Y; Fukushima S; Saito S; Ueno T; Kuratani T; Sawa Y
    Heart Vessels; 2013 Jul; 28(4):490-6. PubMed ID: 22661097
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Postoperative administration of landiolol hydrochloride for patients with supraventricular arrhythmia: the efficacy of sustained intravenous infusion at a low dose.
    Wariishi S; Yamashita K; Nishimori H; Fukutomi T; Yamamoto M; Radhakrishnan G; Sasaguri S
    Interact Cardiovasc Thorac Surg; 2009 Nov; 9(5):811-3. PubMed ID: 19666952
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Practical applicability of landiolol, an ultra-short-acting β1-selective blocker, for rapid atrial and ventricular tachyarrhythmias with left ventricular dysfunction.
    Wada Y; Aiba T; Tsujita Y; Itoh H; Wada M; Nakajima I; Ishibashi K; Okamura H; Miyamoto K; Noda T; Sugano Y; Kanzaki H; Anzai T; Kusano K; Yasuda S; Horie M; Ogawa H
    J Arrhythm; 2016 Apr; 32(2):82-8. PubMed ID: 27092187
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of landiolol hydrochloride for prevention of atrial fibrillation after cardiac surgery in patients with left ventricular dysfunction: Prevention of Atrial Fibrillation After Cardiac Surgery With Landiolol Hydrochloride for Left Ventricular Dysfunction (PLATON) trial.
    Sezai A; Osaka S; Yaoita H; Ishii Y; Arimoto M; Hata H; Shiono M
    J Thorac Cardiovasc Surg; 2015 Oct; 150(4):957-64. PubMed ID: 26254752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Landiolol in the treatment of the intraoperative supraventricular tachycardia: a multicenter, randomized, double-blind, placebo-controlled study.
    Xiao J; He P; Zou Q; Zhao Y; Xue Z; Deng X; Li S; Guo Q; Tao G; Yang T; Lang Z; He J; Wang X
    J Clin Anesth; 2015 Mar; 27(2):120-8. PubMed ID: 25434501
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence, pathophysiology, and clinical significance of post-heart transplant atrial fibrillation and atrial flutter.
    Ahmari SA; Bunch TJ; Chandra A; Chandra V; Ujino K; Daly RC; Kushwaha SS; Edwards BS; Maalouf YF; Seward JB; McGregor CG; Chandrasekaran K
    J Heart Lung Transplant; 2006 Jan; 25(1):53-60. PubMed ID: 16399531
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel use of the ultra-short-acting intravenous β1-selective blocker landiolol for supraventricular tachyarrhythmias in patients with congestive heart failure.
    Adachi T; Sato A; Baba M; Hiraya D; Hasegawa T; Kuroki K; Hoshi T; Aonuma K
    Heart Vessels; 2014 Jul; 29(4):464-9. PubMed ID: 23801459
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Study design for control of HEART rate in inFant and child tachyarrhythmia with heart failure Using Landiolol (HEARTFUL): A prospective, multicenter, uncontrolled clinical trial.
    Sumitomo N; Horigome H; Miura M; Ono H; Ueda H; Takigiku K; Yoshimoto J; Ohashi N; Suzuki T; Sagawa K; Ushinohama H; Takahashi K; Miyazaki A; Sakaguchi H; Iwamoto M; Takamuro M; Tokunaga C; Nagano T;
    J Cardiol; 2017 Sep; 70(3):232-237. PubMed ID: 28073682
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of intravenously administered dofetilide in acute termination of atrial fibrillation and flutter: a multicenter, randomized, double-blind, placebo-controlled trial. Danish Dofetilide in Atrial Fibrillation and Flutter Study Group.
    Nørgaard BL; Wachtell K; Christensen PD; Madsen B; Johansen JB; Christiansen EH; Graff O; Simonsen EH
    Am Heart J; 1999 Jun; 137(6):1062-9. PubMed ID: 10347332
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preventive effect of intraoperative landiolol administration on atrial fibrillation after off-pump coronary artery bypass grafting.
    Osumi M; Tashiro T; Morita Y; Kamiya S; Minematsu N; Nishimi M; Wada H
    Adv Ther; 2014 Oct; 31(10):1109-17. PubMed ID: 25319249
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.